Cytotoxic effects of dynorphins through nonopioid intracellular mechanisms

Experimental Cell Research

Volumn 269, Issue 1, 2001, Pages 54-63

  Tan No, Koichi ^a   Cebers, Gvido ^a   Yakovleva, Tatjana ^a   Hoon Goh, Bee ^a   Gileva, Irina ^a   Reznikov, Kyrill ^a   Aguilar Santelises, Miguel ^a   Hauser, Kurt F ^b   Terenius, Lars ^a   Bakalkin, Georgy ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Apoptosis; Big dynorphin; Cell death; p53

Indexed keywords

DYNORPHIN A; DYNORPHIN B; NALOXONE; POLYLYSINE; PRODYNORPHIN; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL VIABILITY; CYTOTOXICITY; ELECTROPORATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL;

EID: 17944379323     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.2001.5309     Document Type: Article

References (54)

1. Nonopiate effects of dynorphin and des-Tyr-dynorphin
2. Effects of traumatic injury on dynorphin immunoreactivity in spinal cord
3. Endogenous opioid immunoreactivity in rat spinal cord following traumatic injury
4. Increased dynorphin immunoreactivity in spinal cord after traumatic injury
5. Sequential expression of c-fos protooncogene, TNF-alpha, and dynorphin genes in spinal cord following experimental traumatic injury
6. Extraterritorial neuropathic pain correlates with multisegmental elevation of spinal dynorphin in nerve-injured rats
7. Endogenous opioids in spinal cord injury: A critical evaluation
8. Non-opioid effects of dynorphins: Possible role of the NMDA receptor
9. Dynorphin-related peptides cause motor dysfunction in the rat through a non-opiate action
10. Antinociception and paralysis induced by intrathecal dynorphin A
11. Dynorphin A-induced rat hindlimb paralysis and spinal cord injury are not altered by the kappa opioid antagonist nor-binaltorphimine
12. Neurological dysfunction after intrathecal injection of dynorphin A (1-13) in the rat. II. Nonopioid mechanisms mediate loss of motor, sensory and autonomic function
13. Structure-activity analysis of dynorphin A toxicity in spinal cord neurons: Intrinsic neurotoxicity of dynorphin A and its carboxyl-terminal, non-opioid metabolites
14. Single intrathecal injections of dynorphin A or des-Tyrdynorphins produce long-lasting allodynia in rats: Blockade by MK-801 but not naloxone
15. Spinally administered dynorphin A produces long-lasting allodynia: Involvement of NMDA but not opioid receptors
16. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance
17. Competitive and non-competitive NMDA antagonists limit dynorphin A-induced rat hindlimb paralysis
18. Selective potentiation of NMDA-induced activity and release of excitatory amino acids by dynorphin: Possible roles in paralysis and neurotoxicity
19. N-Methyl-D-aspartate (NMDA) and opioid receptors mediate dynorphin-induced spinal cord injury: Behavioral and histological studies
20. Dynorphin A-induced rat spinal cord injury: Evidence for excitatory amino acid involvement in a pharmacological model of ischemic spinal cord injury
21. The opioid peptide dynorphin directly blocks NMDA receptor channels in the rat
22. High-affinity interaction of (des-tyrosyl)-dynorphin A(2-17) with NMDA receptors
23. Dynorphins directly inhibit neuronal nicotinic acetylcholine receptors in PC12 cells
24. Arginine-rich peptides are blockers of VR-1 channels with analgesic activity
25. Both dynorphin A(1-17) and [Des-Tyr1]dynorphin A(2-17) inhibit adenylyl cyclase activity in rat caudate putamen
26. Catalysis of peptide dissociation from class II MHC-peptide complexes
27. Preferred conformation, orientation, and accumulation of dynorphin A-(1-13)-tridecapeptide on the surface of neutral lipid membranes
28. Competitive binding of dynorphin-(1-13) and beta-endorphin to cerebroside sulfate in solution
29. Non-opioid dynorphin binding site on secretory vesicles of a pituitary-derived cell line
30. Behavioral alterations associated with apoptosis and down-regulation of presenilin i in the brains of p53-deficient mice
31. Small peptides activate the latent sequence-specific DNA binding function of p53
32. Regional distribution of dynorphin and neo-endorphin peptides in rat brain, spinal cord, and pituitary
33. The posttranslational processing of prodynorphin in the rat anterior pituitary
34. p53 latency: C-terminal domain prevents binding of p53 core to target but not to nonspecific DNA sequences
35. Expression of preprodynorphin in human small cell lung carcinoma cell lines
36. Characterization of human prodynorphin gene transcripts
37. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture
38. Clustering of apoptotic cells via bystander killing by peroxides
39. A general procedure for analysis of proenkephalin B derived opioid peptides
40. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from p53 C-terminal domain
41. 3H-Naloxone benzoylhydrazone binding in MOR-1-transfected Chinese hamster ovary cells: Evidence for G-protein-dependent antagonist binding
42. Partial agonistic activity of naloxone on the opioid receptors expressed from complementary deoxyribonucleic acids in Chinese hamster ovary cells
43. Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties
44. Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor
45. Antisera against peptides derived from a purified μ-opioid binding protein recognize the protein as well as mu-opioid receptors in brain regions and a cell line
46. Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells
47. Amino acid sequence pattern in the regulatory peptides
48. The binding site for the beta gamma subunits of heterotrimeric G proteins on the beta-adrenergic receptor kinase
49. Modulation of calmodulin plasticity in molecular recognition on the basis of x-ray structures
50. The regulatory region of calcium/calmodulin-dependent protein kinase I contains closely associated autoinhibitory and calmodulin-binding domains
51. Regulation of protein kinase Cmu by basic peptides and heparin. Putative role of an acidic domain in the activation of the kinase
52. The basic domain of myogenic basic helix-loop-helix (bHLH) proteins is the novel target for direct inhibition by another bHLH protein
53. Peptide modulators of protein-protein interactions in intracellular signaling
54. ER quality control: The cytoplasmic connection